Watch ATXI. Know when insiders buy.
One email the day a filing lands. Free.
ATXI
AVENUE THERAPEUTICS, INC.
0.54
−0.03 −4.48%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.8MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$2.8MNET CASH —52W 0.15 – 0.93SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | −100.0% | — | −$707K | −$690K | −306.0% | -0.21 | −$475K | — | — | Aug 7 |
| Q1 2026 · Mar 31 | — | — | — | −$714K | −$695K | — | -0.21 | −$438K | — | — | May 8 |
| Q4 2025 · Dec 31derived | $0 | — | — | −$752K | −$709K | — | -0.22 | −$854K | — | — | Mar 30 |
| Q3 2025 · Sep 30 | $0 | — | — | −$724K | −$683K | — | -0.21 | $383K | — | — | Nov 13 |
| Q2 2025 · Jun 30 | $1.4M | — | — | $297K | $335K | — | 0.11 | −$176K | — | — | Aug 7 |
| Q1 2025 · Mar 31 | — | — | — | −$1.9M | −$1.9M | — | -0.62 | −$1.2M | — | — | May 8 |
| Q4 2024 · Dec 31derived | $0 | — | — | −$1.6M | −$1.5M | −391.9% | 1.48 | −$764K | — | — | Mar 30 |
| Q3 2024 · Sep 30 | $0 | — | — | −$3.2M | −$3.1M | −684.8% | -1.92 | −$2.9M | — | — | Nov 13 |
| Q2 2024 · Jun 30 | $0 | — | — | −$2.8M | −$2.7M | — | -6.43 | −$2.3M | — | — | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$3.7M | −$4.3M | — | -15.40 | −$3.1M | — | — | May 15 |
| Q4 2023 · Dec 31derived | — | — | — | −$2.1M | $529K | — | -71.94 | −$2.3M | — | — | Mar 31 |
| Q3 2023 · Sep 30 | — | — | — | −$2.1M | $526K | — | 0.06 | −$889K | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.4M | — | −$3.1M | −$2.9M | -207.2% | -0.93 | −$1.8M | — | — | — | — |
| FY2024 · to Dec 31 | $0 | — | −$11.3M | −$11.7M | — | -15.79 | −$9M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$14.5M | −$10.5M | — | -73.48 | −$9.5M | — | — | $0 | — |
| FY2022 · to Dec 31 | — | — | −$8M | −$3.6M | — | -1.63 | −$7.6M | — | — | $1.1M | — |
| FY2021 · to Dec 31 | — | — | −$3.7M | −$3.7M | — | -0.22 | −$3.8M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$5.2M | −$5.2M | — | -0.31 | −$4.6M | — | — | — | — |
Every number comes from AVENUE THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.